Univ. of South Florida (USF) College of Medicine ATN CRS
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Casey, Denise
LORIKEET, NCT05848011: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
2
154
Europe, US, RoW
lorigerlimab, MGD019, docetaxel, Taxotere®, Prednisone
MacroGenics
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
09/26
09/27
MOCHA, NCT03497676: More Options for Children and Adolescents (): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

Active, not recruiting
1/2
168
US, RoW
Oral Cabotegravir (CAB), Oral Rilpivirine (RPV), Edurant, Long-Acting Injectable Cabotegravir (CAB LA), Long-Acting Injectable Rilpivirine (RPV LA), Combination Antiretroviral Therapy (cART)
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare
HIV Infections
02/23
06/25
NCT03761017: MGD019 DART® Protein in Unresectable/Metastatic Cancer

Active, not recruiting
1
162
Europe, US, RoW
Lorigerlimab, MGD019
MacroGenics
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer, Advanced Cancer, Solid Tumor, Adult
08/24
01/25
CP-MGC018-02, NCT05293496: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Active, not recruiting
1
278
US
vobramitamab duocarmazine, MGC018, lorigerlimab, MGD019
MacroGenics
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
04/25
06/25
NCT06242470: A Study of MGC026 in Participants With Advanced Solid Tumors

Recruiting
1
230
Europe, US, RoW
MGC026 Dose Escalation, MGC026 Dose for Expansion
MacroGenics
Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer
05/28
10/28

Download Options